Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Crispr-Based Approaches for the Detection and Targeting of Lung Cancer Biomarkers: A New Era in Precision Oncology

View Full Paper
Ask AI
Bookmark
Share

Authors

IMIbtasam MazharMSMaimona SadiaMSMohammad Saleem

Discussion

Loading...

Member takes

Overview

Prospective study finds CRISPR diagnostics achieve 96.7% sensitivity in lung cancer, indicating a step forward for precision oncology.

Key Points

  • The CRISPR-Cas12a assay achieved 96.7% sensitivity and 98.3% specificity for lung cancer detection.
  • Diagnostic comparisons revealed that CRISPR outperformed conventional PCR and next-generation sequencing (NGS).
  • EGFR mutations disruption via CRISPR-Cas9 reduced cell viability by approximately 65%, showcasing its therapeutic potential.
  • These findings suggest that integrating CRISPR tools could transform early diagnosis and tailored treatments in lung cancer.

Cite This Study

Mazhar et al. (2025) studied this question.

synapsesocial.com/papers/68c23b4ab210217d64783bbchttps://doi.org/10.71000/25yfnz11
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CRISPR-mediated modulation of EGFR signaling in lung cancer2025
  2. 2Mismatch-introduced crRNA guided PCR-CRISPR/Cas12a platform improves EGFR point mutation detection in single tumor cell2025
  3. 3Feasibility of a <scp>ctDNA</scp> multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance2025 · 1 citations
  4. 4CRISPR/Cas-based detection strategies for tumor biomarker detection.2025
  5. 5CRISPR-Powered Liquid Biopsies in Cancer Diagnostics2025